Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chloe trial: everolimus plus endocrine therapy in ER+, HER2- metastatic breast cancer
jRCTs061180075Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of everolimus in breast cancer (2 arms), sponsored by Novartis. Primary endpoint: progression-free survival. Started May 2017; status: completed.
02
Drugs
everolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCTs061180075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180075.